Physician profile
Imran Sheriff
NPI 1659373678
$10,292.06
in general payments reported to CMS, 2019-2025
36 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $920 · 2021: $1,923 · 2022: $1,764 · 2023: $1,505 · 2024: $1,678 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,651 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,650.91 |
| Education | $281.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,043.73 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,898.43 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $1,329.88 | 2019-2025 | Vraylar, Linzess, Ubrelvy |
| Astellas Pharma US INC | $912.77 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $660.33 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Pfizer INC. | $534.69 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $495.00 | 2021-2025 | |
| Amgen INC. | $322.40 | 2024-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $303.87 | 2021-2022 | |
| Abbott Laboratories | $230.19 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Lilly USA, LLC | $209.89 | 2022-2024 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $187.07 | 2019-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $137.58 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $104.86 | 2019-2024 | Spravato |
| Exact Sciences Corporation | $98.83 | 2025 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $72.09 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $65.83 | 2022-2023 | Quviviq |
| Ironwood Pharmaceuticals, INC | $63.23 | 2023-2024 | Linzess |
| Biohaven Pharmaceuticals, INC. | $60.72 | 2021 | |
| Eisai INC. | $59.66 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.14 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $48.52 | 2025 | |
| Medtronic, INC. | $43.81 | 2022 | |
| Redhill Biopharma INC. | $42.86 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $42.65 | 2024 | Nuzyra |
| Scilex Pharmaceuticals INC. | $39.61 | 2023-2024 | Ztlido |
| Boston Scientific Corporation | $29.93 | 2025 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $26.35 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $25.88 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $23.90 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.26 | 2022 | |
| Horizon Therapeutics Plc | $22.51 | 2023 | Krystexxa |
| Harmony Biosciences LLC | $21.25 | 2020 | |
| Allergan, INC. | $19.59 | 2019 | |
| Daiichi Sankyo INC. | $19.17 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Sheriff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.